- ¥158bn
- ¥108bn
- ¥97bn
Table: Kissei Pharm -2017/18 parent results
Brief: Kissei Pharmaceutical says change of president
Brief: Kissei Pharmaceutical says rating withdrawal by R&I
Brief: Kissei Pharmaceutical completes share repurchase
Brief: Kissei Pharmaceutical to repurchase up to 3.7 pct shares and retire treasury shares
Table: Kissei Pharm - 9-MTH group results
Brief: JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study
Table: Kissei Pharm - 6-MTH group results
2017 6-month parent forecast
2017 6-month group forecast
Table: Kissei Pharm -Q1 group results
Swiss stocks - Factors to watch on June 9
Brief: Vifor Pharma: Kissei to market avacopan in Japan
Table: Kissei Pharm -2016/17 parent results
Table: Kissei Pharm -2016/17 group results
Brief: R&I affirms Kissei Pharmaceutical's rating at "A-" and says stable outlook - R&I
Table: Kissei Pharm -9-MTH group results
Table: Kissei Pharm -6-MTH group results
Table: Kissei Pharm -Q1 group results